Efficacy and toxicity of neoadjuvant radiotherapy with concomitant dose escalation for rectal cancer
Neoadjuvant chemoradiotherapy with concomitant dose escalation yields high pCR rates for both primary tumor and nodal disease, with acceptable toxicity, in a significant number of patients with rectal cancer. Presence of pCR is associated with markedly improved DFS. Moreover, prolonged interval between neoadjuvant radiotherapy and surgery correlates with elevated pCR rates.
Authors
- D Liu (ORCID: https://orcid.org/0009-0006-3434-5957)
- Ke Hu (ORCID: https://orcid.org/0000-0003-1079-5137)
- Peng Wang (ORCID: https://orcid.org/0000-0002-8241-624X)
- Weiping Wang (ORCID: https://orcid.org/0000-0001-7511-3497)
- Xiaoliang Liu (ORCID: https://orcid.org/0000-0002-3776-6929)
- Yidi Wang (ORCID: https://orcid.org/0000-0002-2400-8109)
- Shuai Sun (ORCID: https://orcid.org/0000-0002-3394-234X)
- Kai Liu (ORCID: https://orcid.org/0000-0003-2933-0356)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fonc.2025.1725405
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Peking Union Medical College Hospital